Gelesis Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLS research report →
Companywww.gelesis.com
Gelesis Holdings Inc. , a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management.
- CEO
- Yishai Zohar
- IPO
- 2022
- Employees
- 93
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $11.63M
- P/E
- -0.20
- P/S
- 0.45
- P/B
- -0.44
- EV/EBITDA
- -0.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -6.95%
- Op Margin
- -472.72%
- Net Margin
- -216.48%
- ROE
- 31.43%
- ROIC
- -137.49%
Growth & Income
- Revenue
- $25.77M · 130.37%
- Net Income
- $-55,780,000 · 40.24%
- EPS
- $-0.79 · 95.17%
- Op Income
- $-121,806,000
- FCF YoY
- -15.48%
Performance & Tape
- 52W High
- $5.67
- 52W Low
- $0.01
- 50D MA
- $0.18
- 200D MA
- $0.61
- Beta
- 0.99
- Avg Volume
- 570.67K
Get TickerSpark's AI analysis on GLS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 20, 23 | PureTech Health plc | buy | 0 |
| Jun 12, 23 | PureTech Health plc | buy | 0 |
| May 26, 23 | PureTech Health plc | buy | 43,133,803 |
| May 26, 23 | PureTech Health plc | buy | 0 |
| May 1, 23 | PureTech Health plc | buy | 192,307,692 |
| May 1, 23 | PureTech Health plc | buy | 23,688,047 |
| May 1, 23 | PureTech Health plc | buy | 5,000,000 |
| May 1, 23 | PureTech Health plc | buy | 2,000,000 |
| Nov 21, 22 | KUCHERLAPATI RAJU S | buy | 92,000 |
| Nov 18, 22 | KUCHERLAPATI RAJU S | buy | 8,000 |
Our GLS Coverage
We haven't published any research on GLS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLS Report →